Vivo Bio Tech Approves FY26 Audited Results, Reappoints Director

Vivo Bio Tech Ltd's board approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The board also approved the re-appointment of Mr. Kalyan Ram Mangipudi as a Whole-time Director for 5 years, subject to shareholder approval. Additionally, the board considered and approved material related party transactions, also subject to shareholder approval via postal ballot, and approved the appointment of a consultant/advisor for a proposed Scheme of Arrangement/Amalgamation.